Clinically provenweight loss treatments
Prescription medications, personalized to your needs, delivered to your door.
Semaglutide vs. tirzepatide: which is right for you?
Two compounded GLP-1 options, side by side, so you and a licensed provider can choose with confidence.
| Compounded semaglutide | Compounded tirzepatide | |
|---|---|---|
| Active ingredient | Semaglutide, the same active ingredient as Wegovy and Ozempic | Tirzepatide, the same active ingredient as Mounjaro and Zepbound |
| How it works | GLP-1 receptor agonist that helps curb appetite and slow digestion | Dual GIP + GLP-1 receptor agonist targeting two appetite pathways |
| Avg. weight loss in trials* | -14.9% at 68 weeks (STEP 1, NEJM 2021) | -20.9% at 72 weeks, 15 mg dose (SURMOUNT-1, NEJM 2022) |
| Dosing | Once-weekly injection, titrated 0.25-2.4 mg | Once-weekly injection, titrated 2.5-15 mg |
| Price (annual plan) | $99/month | $125/month |
A licensed provider reviews your intake and determines what's appropriate. Compounded semaglutide is the lower-cost option; compounded tirzepatide uses a dual-action mechanism. *Trial figures are group averages from studies of the FDA-approved branded medications, not compounded preparations; individual results vary.
The clinical evidence
The same active ingredients have been studied in large, NEJM-published trials of the FDA-approved branded formulations. Trimi's compounded preparations are prepared per individual prescription and are not themselves FDA-approved as drugs.
Semaglutide
The active ingredient in Wegovy and Ozempic
“The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group, as compared with -2.4% with placebo.”
STEP 1, Wilding JPH et al., NEJM 2021;384:989-1002
Tirzepatide
The active ingredient in Mounjaro and Zepbound
“At 72 weeks, the mean percentage change in weight was -20.9% with 15 mg of tirzepatide, as compared with -3.1% with placebo.”
SURMOUNT-1, Jastreboff AM et al., NEJM 2022;387:205-216
These figures are trial averages for the branded formulations; results vary. GLP-1 medications carry risks including nausea, pancreatitis, gallbladder disease, kidney injury, and a boxed warning for thyroid C-cell tumors. This is general information, not medical advice.
How it works
Get started on your weight loss journey in three simple steps
Complete online visit
Answer a few questions about your health and weight loss goals from the comfort of home.
Provider review
A board-certified medical provider will review your information and create your personalized plan.
Receive medication
Your prescription is shipped directly to your door with free shipping and ongoing support.
What's included
One flat monthly price covers clinical care, your medication, and ongoing support. A licensed provider determines whether treatment is appropriate.
Licensed U.S. providers
Care via the Arora Health network, a 50-state US-licensed provider network led by Medical Director Dr. Sean Arora, MD.
503A compounding pharmacies
Dispensed by VialsRx (Texas State Board of Pharmacy license #35264) and GreenwichRx, prepared per individual prescription.
Free shipping
Your medication ships to your door at no extra cost.
Unlimited provider messaging
Message your care team as often as you need between visits.
No insurance needed
Flat monthly pricing, no claims, and no prior authorizations.
Available in all 50 states
Wherever you live in the U.S., treatment may be available pending a provider's review.
Ongoing dose adjustments
Your provider can titrate your dose over time based on how you respond and tolerate it.
Medically reviewed by a licensed provider. Clinical oversight via Dr. Sean Arora, MD, Medical Director.
Frequently asked questions
How does the Trimi Health compounded GLP-1 program work?
You start with an online intake, and a licensed provider from the Arora Health network reviews your health history to decide whether treatment is appropriate. If you're prescribed medication, it's dispensed by a licensed 503A sterile compounding pharmacy (VialsRx, Texas license #35264, or GreenwichRx) and shipped to your door. Your membership includes free shipping, unlimited provider messaging, ongoing dose adjustments, and care in all 50 states with no insurance needed.
Is it safe, and what are the side effects?
Common GLP-1 side effects include nausea, vomiting, diarrhea, and constipation, which often improve as your dose is increased slowly. Serious risks can include pancreatitis, gallbladder disease, and kidney injury, and these medications carry a boxed warning for the risk of thyroid C-cell tumors. They are not appropriate for everyone, including people with a personal or family history of medullary thyroid cancer or MEN 2, or during pregnancy. A licensed provider reviews your history and determines what's appropriate for you.
Should I choose semaglutide or tirzepatide?
Semaglutide is the same active ingredient as Wegovy and Ozempic and is a once-weekly GLP-1 injection. Tirzepatide is the same active ingredient as Mounjaro and Zepbound, a once-weekly dual GIP and GLP-1 injection. In trials of the branded formulations, STEP 1 reported a -14.9% mean body-weight change with semaglutide at 68 weeks, and SURMOUNT-1 reported -20.9% with 15 mg tirzepatide at 72 weeks. Results vary, and a licensed provider helps you decide which fits your goals and history.
Does it work with insurance, and what does it cost?
Trimi Health does not bill insurance, so there's no prior authorization or coverage hassle. On the annual plan, compounded semaglutide is $99 per month and compounded tirzepatide is $125 per month. That price includes free shipping, unlimited provider messaging, and ongoing dose adjustments.
Am I eligible? What about BMI?
Trimi Health generally requires a BMI of 22 or higher to begin intake; this is Trimi's own intake threshold, not a guarantee that treatment is appropriate. A licensed provider makes the final determination based on your full medical history, current medications, and any contraindications.
Are these medications FDA-approved?
The active ingredients, semaglutide and tirzepatide, are FDA-approved in commercial formulations such as Wegovy, Ozempic, Mounjaro, and Zepbound. The compounded preparation you receive from Trimi is made per your individual prescription by a licensed 503A pharmacy and is not itself FDA-approved as a drug. Compounded medications are a long-established part of US pharmacy practice, prepared by state-licensed pharmacies under state board of pharmacy oversight, consistent with Section 503A of the federal Food, Drug, and Cosmetic Act.
Can I switch medications or change my dose later?
Yes. Through unlimited provider messaging, you can talk with your licensed clinician about how treatment is going. They can adjust your dose or switch you between semaglutide and tirzepatide based on your response, tolerability, and goals. Any change is made at the provider's clinical discretion.
Ready to start your journey?
Join thousands who have already lost weight with Trimi
Important safety information
Compounded medications are prepared per individual prescription by licensed 503A community sterile compounding pharmacies (VialsRx, Texas State Board of Pharmacy license #35264; GreenwichRx) and are not FDA-approved as drugs. The active ingredient is FDA-approved in commercial formulations: semaglutide is the same active ingredient as Wegovy and Ozempic, and tirzepatide is the same active ingredient as Mounjaro and Zepbound.
The clinical-trial figures on this page are from studies of the FDA-approved branded medications, not Trimi's compounded preparations, which have not been studied in those trials. Individual results vary based on dose, adherence, and personal health factors.
Possible side effects and serious risks: GLP-1 medications commonly cause nausea and other gastrointestinal effects. Serious risks can include pancreatitis, gallbladder disease, and kidney injury. Boxed warning: in rodent studies these medications caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC); it is not known whether they cause thyroid tumors in humans. Do not use if you or a family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Clinical oversight is provided by Arora Health, a 50-state US-licensed provider network, with Medical Director Dr. Sean Arora, MD. A licensed provider reviews your information and prescribes only where clinically appropriate, including off-label use at their clinical discretion. Trimi's clinicians work alongside your own physician and do not replace them. Available in all 50 US states.
This is general information, not medical advice. Consult a licensed clinician about your individual situation.